NovoCure
ISIN JE00BYSS4X48
|WKN A140ML
Market cap (in EUR)
1,793.92 m
Country
United Kingdom
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Healthcare Healthcare Equipment Other Medical Devices United Kingdom
Financials
Key metrics
| Market capitalisation, EUR | 1,793.92 m |
| EPS, EUR | -1.41 |
| P/B ratio | 5.64 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 559.51 m |
| Net income, EUR | -155.89 m |
| Profit margin | -27.86% |
What ETF is NovoCure in?
There are 30 ETFs which contain NovoCure. All of these ETFs are listed in the table below. The ETF with the largest weighting of NovoCure is the L&G Healthcare Breakthrough UCITS ETF USD Acc.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
